Repligen (NASDAQ:RGEN – Get Free Report) is set to post its quarterly earnings results before the market opens on Wednesday, May 1st. Analysts expect Repligen to post earnings of $0.29 per share for the quarter. Repligen has set its FY 2024 guidance at 1.420-1.490 EPS and its FY24 guidance at $1.42-1.49 EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.
Repligen (NASDAQ:RGEN – Get Free Report) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. The company had revenue of $155.74 million for the quarter, compared to the consensus estimate of $155.38 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The firm’s quarterly revenue was down 16.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.68 EPS. On average, analysts expect Repligen to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Repligen Price Performance
Shares of RGEN opened at $171.28 on Wednesday. The company has a market capitalization of $9.56 billion, a price-to-earnings ratio of 237.89, a P/E/G ratio of 5.16 and a beta of 1.02. Repligen has a fifty-two week low of $110.45 and a fifty-two week high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 7.02 and a quick ratio of 5.75. The business’s 50-day moving average is $186.62 and its 200-day moving average is $173.56.
Insider Buying and Selling at Repligen
Analyst Upgrades and Downgrades
A number of research firms recently commented on RGEN. Stifel Nicolaus increased their price objective on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. KeyCorp increased their price objective on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Repligen currently has an average rating of “Moderate Buy” and a consensus target price of $196.70.
Check Out Our Latest Research Report on Repligen
Repligen Company Profile
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Read More
- Five stocks we like better than Repligen
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Lockheed Martin Stock Aims for a Fresh All-Time High
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.